Stephen H. Tsang, MD, PhD: MCO-010 for Stargardt Disease in STARLIGHT Trial

News
Video

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

New data from the phase 2 STARLIGHT trial suggest the promise of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) optogenetic therapy in patients with Stargadt Disease, according to a presentation at the 127th Annual American Academy of Ophthalmology (AAO) Meeting in San Francisco, California.

Results from the phase 2 STARLIGHT trial showed patients with Stargadt Disease had a mean best-corrected visual acuity improvement of +5.5 ETDRS letters.

“In some suggestions, there are improvements in vision,” presenting investigator Stephen H. Tsang, MD, PhD, a professor of ophthalmology, pathology, and cell biology at Columbia University, told HCPLive. “It would provide support to go into a phase 3 trial in a larger number of patients to see whether or not there is efficacy.”

Stargardt disease is a rare inherited eye disorder caused by fatty deposits in the macula and leads to center-field loss of vision in affected patients. There are approximately 8,000-10,000 patients in the United States, and symptoms often begin in childhood or adolescence. Currently, there are no treatments approved by the US Food and Drug Administration (FDA).

The phase 2 STARLIGHT Trial evaluated the effects of MCO-010 gene therapy on patients with Stargardt disease. MCO-010 uses a well-established intraocular injection for the delivery of a gene that encodes the ambient light-sensitive MCO protein into retinal cells. As a result, the therapy enables retinal cells to detect light, allowing patients with rare retinal diseases, including retinitis pigmentosa or Stargardt disease, to see again.

MCO-010 has been granted Orphan Drug and Fast Track designation by the FDA for both Stargardt Disease and retinitis pigmentosa.

“Since Stargardt, although relatively rare, has a lot of features as in age-related macular degeneration,” Tsang said. “It works on this younger group of patients who have Stargardt juvenile macular degeneration, we hope that it would have a broader impact on age-related macular degeneration as well.”

References

Tsang SH. MCO-010 Optogenetic Therapy for Vision Loss in Stargardt Disease: Topline Data From the Phase 2 STARLIGHT Trial. Presented at the 2023 American Academy of Ophthalmology Annual Meeting, November 3 – 6, 2023.

Recent Videos
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
A panel of 3 experts on dry eye
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.